-
1
Liquid biopsy comprehensive genomic profiling (CGP) enhances precision oncology by providing earlier insights and faster access to targeted therapies.
-
2
Liquid biopsy offers a non-invasive alternative to tissue testing, addressing limitations in obtaining sufficient tumor samples for genomic profiling.
-
3
ctDNA analysis captures tumor heterogeneity and resistance mechanisms, providing a broader view than single tissue biopsies for treatment decisions.
-
4
Integrating liquid biopsy into lung cancer pathways significantly reduces turnaround times for actionable results and accelerates treatment allocation.
-
5
In breast cancer, ctDNA testing for ESR1 mutations demonstrates rapid results and the ability to detect low-frequency variants, aiding therapy guidance.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
